STAT3 and esophageal squamous cell carcinoma: In particular, niclosamide (2.5–10 μM) suppressed the STAT3 signaling pathway in esophageal adenocarcinoma cells (BE3) and esophageal squamous cell carcinoma cells (CE48T and CE81T) by impairing both STAT3 phosphorylation on Y705 residue and STAT3 protein expression.